Italy's ICA imposes a 5 million-euro fine on Aspen after 1,500% hike in cancer drug prices

18 October 2016

The Italian Competition Authority (ICA) has imposed a fine of more than 5 million euros ($5.5 million) on South Africa-based drugmaker Aspen Pharmacare for infringing article 102a of the Treaty on the Functioning of the European Union.

According to the ICA, the company had fixed unfair prices with increases up to 1,500% for life-saving and irreplaceable drugs in the treatment of oncohematological patients, especially children and elderly people.

After purchasing the antitumor drug package from GlaxoSmithKline – the patents for which expired decades ago - Aspen started negotiations with the Italian Medicines Agency (Agenzia Italiana del Farmaco - AIFA) with the sole aim to obtain a high increase in prices, even in the absence of any necessary economic justifications.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK